# Harmony Biosciences Shares First Clinical Data for Orexin-2 Agonist BP-205

> clinical trial · REPORTED · 2026-08-04

Alongside its record Q2 2026 earnings report on August 4, Harmony Biosciences shared initial clinical data for BP-205, its orexin-2 receptor agonist pipeline candidate, with results reinforcing its potential best-in-class profile in neurological disease. WAKIX net revenue grew 30% year-over-year to $261.3 million and the company reiterated its full-year 2026 guidance of $1.0 billion.

About Harmony Biosciences: Harmony Biosciences is a Nasdaq-listed pharmaceutical company dedicated to rare neurological diseases; its marketed product WAKIX treats narcolepsy and its pipeline includes novel orexin-pathway therapies.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://www.benzinga.com/markets/earnings/26/08/60942069/harmony-biosciences-says-new-data-supports-neurology-pipeline

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.